$LRMR very terrible data update. 1) data leakage is obvious; 2)very high drop out rate, very limited patient for 12-month and 18-month efficacy; 3) no USS reported for efficacy to derisk phase3; 4) tolerability remaining a issue for comercial; 5) no report baseline of NRF2 treat